Receives $15.00 Consensus Price Target from Brokerages
Molecular Templates log Molecular Templates Inc (NASDAQ: MTEM) has obtained a mean rating of “Hold” from the 11 scores companies presently protecting the inventory, MarketBeat Rating reviews. In addition, three equities research analysts have rated the inventory with a promote score, and 7 have assigned a buy score to the company. The average twelve-month target charge amongst brokerages that have issued a document at the inventory inside the closing yr is $15.00.
Several studies analysts have lately weighed in on MTEM shares. Zacks Investment Research downgraded Molecular Templates from a “hold” score to a “sell” score in studies. Be aware on Friday, August 16th. UBS Group commenced insurance on Molecular Templates in a research observe on Monday, April 29th. They issued a “purchase” rating and a $12.00 goal price for the agency. Cowen restated a “purchase” rating on stocks of Molecular Templates in a studies word on Tuesday, August 13th. BidaskClub downgraded Molecular Templates from a “maintain” rating to a “sell” score in a research observe on Friday, July 26th. Finally, TheStreet downgraded Molecular Templates from a “c-” score to a “d” rating in a research word on Monday, August 5th.
MTEM inventory opened at $5.00 on Thursday. The organization has a debt-to-fairness ratio of 0.15, a short ratio of 3.11, and a contemporary ratio of 3.11. The organization has a marketplace capitalization of $193.55 million, a charge-to-income ratio of -4.Ninety and a beta of 2.77. Molecular Templates has a 52 week low of $3.19 and a 52 week high of $8.77. The stock has a 50 day shifting common of $6.41 and a two hundred-day moving average of $6.48.
Molecular Templates (NASDAQ: MTEM) ultimately published its quarterly profits consequences on Monday, August twelfth. The biotechnology organization mentioned ($0.25) income in keeping with proportion for the area, lacking the consensus estimate of ($0.23) using ($0.02). The firm had sales of $5.45 million for the sector compared to the consensus estimate of $6.00 million. Molecular Templates negatively affected the fairness of 27.72% and a terrible internet margin of 113.85%. Equities analysts expect that Molecular Templates will put up -0.92 EPS for the contemporary yr.
A quantity of hedge price range and other institutional buyers have changed their commercial enterprise holdings these days. BlackRock Inc. Boosted its function in stocks of Molecular Templates by 51.1% at some stage in the second zone. BlackRock Inc. Now owns 1,080,557 stocks of the biotechnology organization’s stock worth $9,023,000 after acquiring an additional 365,350 stocks during the last quarter. Point72 Asset Management L.P. bought a brand new stake in stocks of Molecular Templates during the 2nd region worth approximately $1,682,000. Vanguard Group Inc. boosted its position in shares of Molecular Templates via 10.4% at some stage in the 2d sector. Vanguard Group Inc.
Now owns 740,883 shares of the biotechnology organization’s stock valued at $6,187,000 after obtaining an extra 69,704 stocks over the last zone. In addition, Renaissance Technologies LLC boosted its position in shares of Molecular Templates by using 453.7% at some point in the second quarter. Renaissance Technologies LLC now owns 81,400 stocks of the biotechnology company’s stock valued at $680,000 after acquiring an additional 66,700 stocks over the last quarter. Finally, Wells Fargo & Company MN boosted its role in stocks of Molecular Templates by using 557.7% in the second region. Wells Fargo & Company MN now owns 78,381 stocks of the biotechnology corporation’s stock valued at $654,000 after obtaining a further 66,464 shares over the past quarter. Institutional buyers and hedge funds personal 38.29% of the enterprise’s inventory.
About Molecular Templates
Molecular Templates, Inc, a scientific stage oncology organization, focuses on discovering and developing biological therapeutics for the remedy of cancer and different illnesses. The corporation primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 in Phase II clinical trial to treat relapsed/refractory diffuse big B-cellular lymphoma; and a Phase II medical trial for treating non-Hodgkin’s lymphoma.